December 19, 2025

Data Published on Incidence of Immune Checkpoint Inhibitor–Associated ITP

Valuable information has been published about a rare but serious complication of cancer immunotherapy—immune checkpoint inhibitor–associated immune thrombocytopenia—providing the first large-scale des...

The ASCO Post

December 19, 2025

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor ponatinib and the bispecific T-cell engager bl...

The ASCO Post

December 19, 2025

IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer

Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to phase III data.

The ASCO Post

December 19, 2025

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

The ASCO Post

December 18, 2025

Andrew A. Lane, MD, PhD discuss results from a phase 2 Study

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)

Dana-Farber

December 18, 2025

Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer

The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining...

The ASCO Post

December 18, 2025

FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma

On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuv...

The ASCO Post

December 18, 2025

FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer

The PARP inhibitor was approved for adults with deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor–directed therapy.

The ASCO Post

December 17, 2025

FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma

On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who...

The ASCO Post